JP2024520421A5 - - Google Patents

Info

Publication number
JP2024520421A5
JP2024520421A5 JP2023572788A JP2023572788A JP2024520421A5 JP 2024520421 A5 JP2024520421 A5 JP 2024520421A5 JP 2023572788 A JP2023572788 A JP 2023572788A JP 2023572788 A JP2023572788 A JP 2023572788A JP 2024520421 A5 JP2024520421 A5 JP 2024520421A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
fusion protein
deletions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023572788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520421A (ja
JP7905369B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030658 external-priority patent/WO2022251168A1/en
Publication of JP2024520421A publication Critical patent/JP2024520421A/ja
Priority to JP2025086967A priority Critical patent/JP2025116068A/ja
Publication of JP2024520421A5 publication Critical patent/JP2024520421A5/ja
Application granted granted Critical
Publication of JP7905369B2 publication Critical patent/JP7905369B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023572788A 2021-05-25 2022-05-24 腎臓活性融合タンパク質及びそれを使用する治療方法 Active JP7905369B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025086967A JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192835P 2021-05-25 2021-05-25
US63/192,835 2021-05-25
PCT/US2022/030658 WO2022251168A1 (en) 2021-05-25 2022-05-24 Kidney active fusion proteins and methods of treatment using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025086967A Division JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Publications (3)

Publication Number Publication Date
JP2024520421A JP2024520421A (ja) 2024-05-24
JP2024520421A5 true JP2024520421A5 (cg-RX-API-DMAC7.html) 2025-06-04
JP7905369B2 JP7905369B2 (ja) 2026-08-14

Family

ID=84230212

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023572788A Active JP7905369B2 (ja) 2021-05-25 2022-05-24 腎臓活性融合タンパク質及びそれを使用する治療方法
JP2025086967A Pending JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025086967A Pending JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Country Status (11)

Country Link
US (1) US20240262877A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347666A4 (cg-RX-API-DMAC7.html)
JP (2) JP7905369B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240013770A (cg-RX-API-DMAC7.html)
CN (1) CN117396519A (cg-RX-API-DMAC7.html)
AU (1) AU2022283254A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024627A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177162A1 (cg-RX-API-DMAC7.html)
IL (1) IL308754A (cg-RX-API-DMAC7.html)
MX (1) MX2023014037A (cg-RX-API-DMAC7.html)
WO (1) WO2022251168A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116472065A (zh) * 2020-10-05 2023-07-21 阿雷克森制药公司 治疗皮肌炎的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527115A (ja) 2000-03-13 2003-09-16 セント ビンセンツ ホスピタル 新規のh因子関連タンパク質5及びその抗体
JP5250548B2 (ja) * 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体h因子の標的化
AU2011222883B2 (en) 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
EP3033093A1 (en) * 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
WO2018075462A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury
WO2020041644A1 (en) * 2018-08-22 2020-02-27 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same

Similar Documents

Publication Publication Date Title
TWI648401B (zh) 生長分化因子15(gdf-15)構築體
JP4958975B2 (ja) インスリン様増殖因子iの製造方法
US10913790B2 (en) Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules
CN101511390B (zh) 制备胰岛素样生长因子-1与聚(乙二醇)的偶联物的方法
JP2014519852A5 (cg-RX-API-DMAC7.html)
RU2011138951A (ru) Пропротеины и способы их применения
JP2014522641A (ja) リラキシン融合ポリペプチドおよびその使用
CN108992661B (zh) 一种多肽在制备静脉、腹腔或鼻腔给药药物中的应用
JP2015504675A5 (cg-RX-API-DMAC7.html)
JP2024016234A (ja) 変異型rsv fタンパク質及びその利用
JP2011518179A5 (cg-RX-API-DMAC7.html)
JP2014520148A (ja) 治療のための神経筋接合部への標的化
CN109106942B (zh) 一种可通过血脑屏障的多肽在制备药物中的应用
TW200526780A (en) TNF antagonists and TNF inhibitors comprising the same as the active ingredient
JP2022118184A (ja) コンジュゲートされたc1エステラーゼインヒビター及びその使用
JP2002511847A (ja) Porphyromonas gingivalisに関連した歯周病の診断および治療のための合成ペプチド構築物
CN109232744B (zh) 改进型齐考诺肽
CN109265558B (zh) 改进型齐考诺肽在制备药物中的应用
KR20220012227A (ko) Clec9a-기반 키메라 단백질 복합체
CN118922203A (zh) 嵌合多肽
EP2846819A1 (en) Variants of tace pro-domain as tnf-a inhibitor and their medical use
JP6675306B2 (ja) かゆみの抑制
CN109232746B (zh) 一种齐考诺肽和tat肽的融合多肽
CA2223503A1 (en) Transferrin receptor genes
WO2023196913A2 (en) Methods of treating ankylosing spondylitis